HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study

被引:3
作者
Kim, So Won [1 ,3 ]
Yu, Hoon [3 ,6 ]
Kim, Younjuong [2 ]
Nam, Kyeng Hyun [2 ]
Chae, Han Kyu [4 ]
Nam, Wook [4 ]
Eom, Dae-Woon [5 ]
Park, Jong Yeon [4 ]
Kim, Sung Jin [3 ,4 ,7 ]
机构
[1] Univ Ulsan, Coll Med, Dept Pharmacol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
[3] Univ Ulsan, Biomed Inst Technol, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Urol, Kangnung, South Korea
[5] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Pathol, Kangnung, South Korea
[6] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Nephrol, Kangnung, South Korea
[7] Univ Ulsan, Gangneung Asan Hosp, Coll Med, Dept Urol, Bangdong Gil 38, Gangneung Si 25440, Gangwon Do, South Korea
基金
新加坡国家研究基金会;
关键词
HER2; neoadjuvant chemotherapy; radical cystectomy; urinary bladder neoplasms; NEOADJUVANT CHEMOTHERAPY; UROTHELIAL CARCINOMA; CELL-CARCINOMA; SUBTYPES; IDENTIFICATION; AMPLIFICATION; TRASTUZUMAB; EXPRESSION; GRADE; BASAL;
D O I
10.1097/JS9.0000000000000859
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Human epidermal growth factor receptor type 2 (HER2) overexpression is a prognostic factor and a therapeutic target for breast cancer; however, anti-HER2 therapies are ineffective in patients with bladder cancer. The authors investigated the effect of HER2 overexpression (HER2(+)) on the prognosis of muscle-invasive bladder cancer (MIBC). Materials and methods: This retrospective cohort study included patients who underwent initial transurethral resection of bladder tumors between 2005 and 2013 and were registered in the Korea National Health Insurance Database, which provides data on overall survival (OS). Sixty-one patients with clinically nonmetastatic de novo MIBC were included in this study. As a subgroup, 33 patients who underwent immediate radical cystectomy (RC) were analyzed. Univariate and multivariate Cox proportional hazards models were used to identify prognostic factors for survival. A multivariable binary logistic regression model was used to identify the favorable T stage. Results: Among the 61 patients with d-MIBC, 14 were HER2(+) and 47 HER2(-). Age less than 70 years [hazard ratio (HR): 0.312, CI: 0.16-0.59, P<0.001] and HER2(+) status (HR: 0.40, CI: 0.19-0.85, P=0.02) were favorable prognostic factors for OS after adjusting for clinical variables. In the RC subgroup, HER2(+) status was a significant predictive factor for the pT2 stage (HR): 36.8, CI: 4.83-797.41, P<0.01). Age less than 70 years (HR: 0.15, CI: 0.05-0.42, P<0.001) and HER2(+) status (HR: 0.11, CI: 0.02-0.54, P=0.01) were favorable prognostic factors for OS after adjusting for RC pathological variables. Conclusions: HER2(+) status could be a marker for an indolent subset of MIBC and could predict favorable survival regardless of RC status. Moreover, HER2(+) status not only consistently predicted a favorable T stage after RC, but also predicted better survival than pathological outcomes.
引用
收藏
页码:847 / 858
页数:12
相关论文
共 39 条
[1]  
Bang YJ, 2010, LANCET, V376, P1302
[2]   Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen [J].
Chae, Han Kyu ;
Nam, Wook ;
Kim, Han Gwun ;
Lim, Sharon ;
Noh, Byeong-Joo ;
Kim, So Won ;
Kang, Gil Hyun ;
Park, Jong Yeon ;
Eom, Dae-Woon ;
Kim, Sung Jin .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[3]   Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy [J].
Choi, Woonyoung ;
Porten, Sima ;
Kim, Seungchan ;
Willis, Daniel ;
Plimack, Elizabeth R. ;
Hoffman-Censits, Jean ;
Roth, Beat ;
Cheng, Tiewei ;
Mai Tran ;
Lee, I-Ling ;
Melquist, Jonathan ;
Bondaruk, Jolanta ;
Majewski, Tadeusz ;
Zhang, Shizhen ;
Pretzsch, Shanna ;
Baggerly, Keith ;
Siefker-Radtke, Arlene ;
Czerniak, Bogdan ;
Dinney, Colin P. N. ;
McConkey, David J. .
CANCER CELL, 2014, 25 (02) :152-165
[4]   Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use [J].
Dadhania, Vipulkumar ;
Zhang, Miao ;
Zhang, Li ;
Bondaruk, Jolanta ;
Majewski, Tadeusz ;
Siefker-Radtke, Arlene ;
Guo, Charles C. ;
Dinney, Colin ;
Cogdell, David E. ;
Zhang, Shizhen ;
Lee, Sangkyou ;
Lee, June G. ;
Weinstein, John N. ;
Baggerly, Keith ;
McConkey, David ;
Czerniak, Bogdan .
EBIOMEDICINE, 2016, 12 :105-117
[5]   Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology [J].
Damrauer, Jeffrey S. ;
Hoadley, Katherine A. ;
Chism, David D. ;
Fan, Cheng ;
Tiganelli, Christopher J. ;
Wobker, Sara E. ;
Yeh, Jen Jen ;
Milowsky, Matthew I. ;
Iyer, Gopa ;
Parker, Joel S. ;
Kim, William Y. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (08) :3110-3115
[6]   Cancer statistics for the year 2020: An overview [J].
Ferlay, Jacques ;
Colombet, Murielle ;
Soerjomataram, Isabelle ;
Parkin, Donald M. ;
Pineros, Marion ;
Znaor, Ariana ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) :778-789
[7]   Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours [J].
Fleischmann, Achim ;
Rotzer, Diana ;
Seiler, Roland ;
Studer, Urs E. ;
Thalmann, George N. .
EUROPEAN UROLOGY, 2011, 60 (02) :350-357
[8]  
Grivas PD, 2011, AM J TRANSL RES, V3, P362
[9]   ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy [J].
Groenendijk, Floris H. ;
de Jong, Jeroen ;
van de Putte, Elisabeth E. Fransen ;
Michaut, Magali ;
Schlicker, Andreas ;
Peters, Dennis ;
Velds, Arno ;
Nieuwland, Marja ;
van den Heuvel, Michel M. ;
Kerkhoven, Ron M. ;
Wessels, Lodewijk F. ;
Broeks, Annegien ;
van Rhijn, Bas W. G. ;
Bernards, Rene ;
van der Heijden, Michiel S. .
EUROPEAN UROLOGY, 2016, 69 (03) :384-388
[10]   HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 [J].
Hanker, Ariella B. ;
Garrett, Joan T. ;
Estrada, Monica Valeria ;
Moore, Preston D. ;
Ericsson, Paula Gonzalez ;
Koch, James P. ;
Langley, Emma ;
Singh, Sharat ;
Kim, Phillip S. ;
Frampton, Garrett M. ;
Sanford, Eric ;
Owens, Philip ;
Becker, Jennifer ;
Groseclose, M. Reid ;
Castellino, Stephen ;
Joensuu, Heikki ;
Huober, Jens ;
Brase, Jan C. ;
Majjaj, Samira ;
Brohee, Sylvain ;
Venet, David ;
Brown, David ;
Baselga, Jose ;
Piccart, Martine ;
Sotiriou, Christos ;
Arteaga, Carlos L. .
CLINICAL CANCER RESEARCH, 2017, 23 (15) :4323-4334